India to review protocol for the treatment of Covid-19, the decision taken after study of WHO
Indian health authorities have decided that they will review the protocol being used in the treatment of covid19. This decision has been taken after the results of a major test of the World Health Organization. Four of the commonly used drugs have been found to have no benefit in reducing fatalities in hospitalized patients. These include the antiviral drug remedivir, the malaria drug hydroxychloroquine (HCQ), anti-HIV combination lopinavir and ritonavir, and the immunomodulator interferon. The first two of these drugs are prescribed for a coronavirus patient.
A senior official of the Union Ministry of Health and Family Welfare said that the protocol would be reviewed at the next Joint Task Force meeting, chaired by Dr. VK Paul, Member (Health), Neetioga and Dr. Balram Bhargava, Director General of Indian Council of Medical Research (ICMR). will do. Dr. Bhargava told Hindustan Times, "Yes, we will revisit the clinical management protocol in the light of new evidence before us." Whereas HCQ has been approved by the Drugs Controller General of India for off-label use in moderately ill covid19 patients. Remedisvir has been approved under the Emergency Treatment Authority. The study, known as WHO's Solidarity Trial, says that 405 hospitals in 30 countries now doubt the effectiveness of these drugs.
Data were randomized and taken from 11,266 adults undergoing treatment with covid19. Of them, 2,750 were allocated with Remedisvir, 954 HCQ, 1,411 lopinavir, 651 interferons plus lopinavir, 1,412 interferons only, and 4,088 without any study drug. India was also a part of the trials and tested these four drugs. Experts say that some important questions have been answered in this test.
Dr. K Srinath Reddy, the founder of the Public Health Foundation of India and co-author of this study, said, "The purpose of this test was to see if these drugs work." We have found the answer that these do not work, and it was important to get this answer. Then there are some soft endpoints such as any special subgroups that benefit more. As Americans are saying that it has cut recovery time, as we will know as the trial continues "After the test results are out, WHO indicated that it will make changes to its test. WHO statement" New "Antiviral drugs, immunomodulators, and anti-SARS COV-2 monoclonal antibodies are now being considered for evaluation."